You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》武田藥品(TAK.US)首財季純利跌14.9%遜預期 維持全年度盈測不變
日本藥業巨擘武田藥品(TAK.US)公布截至6月底止首財季業績,受惠日圓轉弱及腫瘤科外核心業務板塊增長,以實際匯率計,收入按年升8.9%至1.06萬億日圓。國際通用會計準則(IFRS)計,季內經營溢利按年升12%至1,686億日圓;以非國際通用會計準則(non-IFRS)計,季內核心經營溢利按年升2.3%至3,263億日圓;核心經營溢利率達30.8%。 IFRS計首財季純利跌14.9%至894億日圓,低於市場預期的1,135.3億日圓;non-IFRS計首財季核心純利則按年升4.1%至2,334億日圓。 公司管理層維持全年度收入及純利預測不變。武田藥品首席財務官Costa Saroukos稱,預期今財年仍面對業務阻力,主要受仿製藥競爭影響,但仍有信心短期內恢復增長。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account